ClinicalTrials.gg
RecruitingNCT07701772PSD-L-FUpdated Sep 1, 2026

LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE

An interventional study of Laser Ablation and Crystallized phenol application in Sacrococcygeal Pilonidal Sinus Disease and Pilonidal Sinus Disease, sponsored by Sanliurfa Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Sanliurfa Education and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,107 studies in Pain, Postoperative with a site in Turkey — 266 open to participants now, 300 under way, none of them phase 3. Pain, Postoperative · Turkey.

Planned enrollment
91st of 892
120 · median 70
Started
2026
with 227 others
No phase
823 of 1,107
220 open now
Primary completion
2027-03
later than 222 of 299 live
Registered
979th of 1,107
by date

Among the 1,107 studies in Pain, Postoperative with a site in Turkey, this one is the 91st largest by planned enrollment of the 892 interventional ones that give a count, is one of 228 that started in 2026, is one of 823 with no phase, reaches primary completion later than 222 of the 299 other live ones, and was the 979th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

266 of the 1,107 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

261 more — sign in →

All 266 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,107 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

This single-center prospective randomized parallel-group trial compares laser ablation and crystallized phenol application in adults with primary uncomplicated sacrococcygeal pilonidal sinus disease. The primary objective is to compare postoperative day 1 pain intensity between the two treatment methods. Secondary objectives include complete epithelialization by day 30, time to complete epithelialization, postoperative day 7 pain, duration of analgesic use, time to return to daily activities and work, early local complications, and 6-month recurrence.

Read the detailed description

This is a single-center, prospective, 1:1 parallel-group randomized clinical trial in adults with primary uncomplicated chronic sacrococcygeal pilonidal sinus disease. A total of 120 participants are planned, with 60 assigned to laser ablation and 60 assigned to crystallized phenol treatment. Randomization will be performed using computer-generated variable blocks, with stratification by pit number and Guner stage when feasible. Allocation concealment will be ensured using sequentially numbered, opaque, sealed envelopes. In both groups, a small incision of approximately 1 cm will be made, hair and debris within the sinus cavity will be removed, and curettage will be performed. After these shared preparation steps, the intervention group will receive Leonardo Mini 1470 nm diode laser treatment and the comparison group will receive crystallized phenol application. Repeat sessions with the same assigned treatment may be performed when needed within the secondary healing protocol. The primary endpoint is postoperative day 1 pain intensity measured by Visual Analog Scale. The main secondary endpoint is complete epithelialization at day 30. Other secondary outcomes include time to complete epithelialization, postoperative day 7 pain, duration of analgesic use, time to return to daily activities and work, early local complications, and recurrence at 6 months.

03

Conditions studied

  • Sacrococcygeal Pilonidal Sinus Disease
  • Pilonidal Sinus Disease

Keywords

  • Pilonidal sinus disease
  • Laser ablation
  • Crystallized phenol
  • Randomized trial
  • Postoperative pain
  • Recurrence
  • Complete epithelialization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of primary chronic sacrococcygeal pilonidal sinus disease
  • Uncomplicated disease
  • Suitability for minimally invasive treatment
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Acute pilonidal abscess
  • History of pilonidal abscess drainage
  • Previous surgical or interventional treatment for pilonidal sinus disease
  • Recurrent pilonidal disease
  • Complex pilonidal disease or marked lateral extension
  • , chronic use, or systemic conditions that may significantly impair wound healing
  • Inability to attend regular follow-up
  • Refusal to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Laser ablation

    Participants undergo shared sinus preparation followed by laser ablation using a Leonardo Mini 1470 nm diode laser.

    Procedure: Laser Ablation

  • Active comparator
    Crystallized phenol

    Participants undergo shared sinus preparation followed by crystallized phenol application to the sinus cavity.

    Procedure: Crystallized phenol application

Interventions

  • ProcedureLaser Ablation

    After a small incision, hair and debris removal, and curettage, laser ablation is performed using a Leonardo Mini 1470 nm diode laser.

  • ProcedureCrystallized phenol application

    After a small incision, hair and debris removal, and curettage, crystallized phenol is applied to the sinus cavity.

06

What researchers measure

Primary outcomes

  1. Postoperative day 1 pain score

    Pain intensity on postoperative day 1 assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.

    Time frame: Postoperative day 1

Secondary outcomes

  1. Complete epithelialization at day 30

    Presence or absence of complete epithelialization of the wound at postoperative day 30.

    Time frame: Postoperative day 30

  2. Time to complete epithelialization

    Time from treatment to complete epithelialization, measured in days.

    Time frame: Up to 30 days

  3. Postoperative day 7 pain score

    Pain intensity on postoperative day 7 assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.

    Time frame: Postoperative day 7

  4. Duration of analgesic use

    Duration of postoperative analgesic use, measured in days.

    Time frame: Up to 30 days

  5. Time to return to daily activities

    Time required to return to normal daily activities, measured in days.

    Time frame: Up to 30 days

  6. Time to return to work

    Time required to return to work, measured in days.

    Time frame: Up to 30 days

  7. Incidence of early local complications

    Number and proportion of participants who develop any early local postoperative complication.

    Time frame: Within 30 days after treatment

  8. Recurrence at 6 months

    Presence or absence of recurrent pilonidal sinus disease by 6 months after treatment.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because this is a single-center clinical study involving sensitive patient-level data, and there is no pre-specified institutional mechanism for external data sharing. Only aggregated, de-identified study results will be reported.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 7 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07701772
Lead sponsor
Sanliurfa Education and Research Hospital
Responsible party
Vedat Kaplan (Principal Investigator, Sanliurfa Education and Research Hospital) — Principal investigator
First posted
Jul 14, 2026
Start date
Jul 15, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Vedat Kaplan
Contact
vedat_kaplan_@hotmail.com
+905459045165

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion